Market cap
$577 Mln
Recently Viewed
Clear All$5.59
$0.00 (0.00%)As on 31-Mar-2022 09:30EDT
Market cap
$577 Mln
Revenue (TTM)
$84 Mln
P/E Ratio
6.8
P/B Ratio
3.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$85 Mln
ROE
0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
11.7
Debt to Equity
0.3
Book Value
$1.8
EPS
$0.8
Face value
--
Shares outstanding
103,229,000
CFO
$-113.94 Mln
EBITDA
$-124.69 Mln
Net Profit
$-148.09 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioDelivery Sciences International Inc (BDSI)
| 80.3 | 0.7 | 81.5 | 49.1 | 1.8 | 24.4 | 8.7 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
BioDelivery Sciences International Inc (BDSI)
| -26.2 | -33.5 | 70.8 | 25.3 | 68.6 | -63.5 | -60.1 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioDelivery Sciences International Inc (BDSI)
|
5.6 | 577.1 | 166.7 | 84.9 | 44.1 | 57.3 | 6.8 | 3.1 |
| 12.8 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 41.0 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 184.0 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 70.9 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.6 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 21.8 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 224.9 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 | |
| 38.2 | 3,287.6 | 158.3 | -68.9 | -29.3 | -113 | -- | 73.8 | |
| 56.7 | 3,736.3 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.2 |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its... products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc. Read more
CEO & Director
Mr. Jeffrey Allen Bailey
CEO & Director
Mr. Jeffrey Allen Bailey
Headquarters
Raleigh, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BioDelivery Sciences International Inc (BDSI) is $5.59 (NASDAQ) as of 31-Mar-2022 09:30 EDT. BioDelivery Sciences International Inc (BDSI) has given a return of 1.79% in the last 3 years.
The P/E ratio of BioDelivery Sciences International Inc (BDSI) is 6.82 times as on 31-Mar-2022.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
3.76
|
1.70
|
|
2020
|
17.15
|
4.07
|
|
2019
|
-34.27
|
7.52
|
|
2018
|
-6.88
|
7.84
|
|
2017
|
31.26
|
18.61
|
The 52-week high and low of BioDelivery Sciences International Inc (BDSI) are Rs -- and Rs -- as of 30-Apr-2026.
BioDelivery Sciences International Inc (BDSI) has a market capitalisation of $ 577 Mln as on 31-Mar-2022. As per SEBI classification, it is a company.
Before investing in BioDelivery Sciences International Inc (BDSI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.